Fax: (860) 545-5112
Disease-specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three-dimensional conformal radiotherapy
Article first published online: 14 OCT 2003
Copyright © 2003 American Cancer Society
Volume 98, Issue 11, pages 2335–2343, 1 December 2003
How to Cite
Staff, I., Salner, A., Bohannon, R., Panatieri, P. and Maljanian, R. (2003), Disease-specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three-dimensional conformal radiotherapy. Cancer, 98: 2335–2343. doi: 10.1002/cncr.11805
- Issue published online: 17 NOV 2003
- Article first published online: 14 OCT 2003
- Manuscript Accepted: 22 AUG 2003
- Manuscript Revised: 18 AUG 2003
- Manuscript Received: 15 APR 2003
- prostatic neoplasms;
- conformal radiotherapy;
- quality of life;
- neoadjuvant therapy;
Approximately 189,000 men are diagnosed with prostate carcinoma each year and more than 1 million are living with the disease. Good prognoses and undesirable sequelae accompany each of several available primary and adjuvant treatment options. The current study explored the effects of primary three-dimensional conformal radiotherapy with or without neoadjuvant hormonal therapy on urinary, bowel, and sexual symptoms and health-related quality of life (HRQOL).
A prospective, repeated-measures design study included 100 patients. Data from the Medical Outcomes Study Short Form Health Survey (a measure of general HRQOL) and a 12-item symptom questionnaire were collected before the start of radiotherapy, approximately 1–3 months after completion of treatment, and again approximately 5–10 months after completion of treatment for follow-up.
Patients reported few urinary symptoms after treatment. Bowel frequency and urgency were reported more frequently posttreatment and at follow-up. Erectile difficulties, which were common pretreatment, were reported with increased frequency posttreatment and at follow-up. General HRQOL scores were higher than age-related general population norms for men at all three data collection times, but there were significant losses posttreatment for patients' physical functioning and vitality. At the 5–10-month follow-up, physical functioning remained lower but vitality scores regained some of the losses. A more extended follow-up is needed. Neoadjuvant therapy, which was received before the pretreatment data collection, had a deleterious effect on erectile functioning but no interactive effects with the radiotherapy on symptoms or HRQOL.
Although patients with a diagnosis of prostate carcinoma experienced increased bowel and sexual dysfunction and decreased vitality after radiotherapy, their HRQOL scores remained at or above age-related general population norms. Cancer 2003. © 2003 American Cancer Society.